Cancer is 2nd leading cause of death and results in an economic burden in excess of 30 billion rupees annually in Pakistan. Each year over 300,000 patients are diagnosed with cancer and 150,000 die from it.
Cancer patients have to undergo costly and ineffective chemotherapy. Newer safer and effective targeted cancer therapies are not available because of lack of complimentary genetic testing services.
Bukhari Genomics has the technology and expertise to launch 12 genomic tests that can be used to diagnose and screen all major types and stages of cancer for personalized and effective cancer therapy.
Important disease related informational links:
www.who.int/cancer/country-profiles/pak_en.pdf
www.cdc.gov/globalhealth/countries/pakistan/default.htm
www.nation.com.pk/28-Apr-2017/prevalence-of-cancer-in-pakistan
Bukhari Genomics is a privately held company committed to the development and commercialization of technologies for accurate and early detection of cancer and inherited disorders. Through unique expertise, exclusive agreements and leading-edge bio-technologies, Bukhari Genomics is offering diagnostic products that are compelling for the healthcare marketplace. The leadership team is composed of successful veterans of diagnostics, medicine and biotech industries.
Company news
Press Releases